Weight Control at WeightControl.com

Study Evaluates Weight Control In Overweight Patients after Tirzepatide (Zepbound) Cessation

The body weight will be somehow regained after cessation of incretin based anti-obesity medicines.

WeightControl.com Interview with:
Xiaoying Li, MD
Professor and Director
Ying Chen, MD
Associate Professor

Department of Endocrinology and Metabolism
Zhongshan Hospital, Fudan University
Shanghai 200032 China

WeightControl.com: What is the background for this study?

Response: Overweight and obesity affect more than 50% of the population in China. In the SUROMOUNT-CN study, we have reported that the GIP/GLP-1 RA, tirzepatide led to a substantial weight loss of 14.4% and 19.9% by 10 mg and 15 mg treatment for 52 weeks, respectively, in overweight or obese Chinese adults. This observational study further evaluated weight loss maintenance following tirzepatide discontinuation.

Pages: 12

Study Finds Weight Regained After Obesity Meds Discontinued

These medications appear to act as ongoing tools for weight maintenance, suggesting they should be viewed as chronic therapies rather than short-term interventions.

WeightControl.com Interview with:
Eric C. Nemec PharmD MEHP BCPS
Director of Research and Assessment
Associate Professor
Master of Physician Assistant Program
Sacred Heart University
Office location: 4 Hospital Plaza, Tandet Center, Stamford, CT 06902

WeightControl.com: What is the background for this study?

Response: When we started this project, we knew that glucagon-like peptide-1 receptor agonists (GLP-1RAs) were highly effective for weight loss; however, there was limited evidence regarding the sustainability of that weight loss after treatment cessation.

Our study systematically reviewed and meta-analyzed randomized controlled trials to determine the extent of weight regain after GLP-1RA discontinuation. The key finding was that significant weight is regained after stopping therapy, and this regain was proportional to the amount initially lost.

Pages: 12

JAMA Network Open Study Evaluates Which Patients Are More Likely To Discontinue Obesity Medications

Patients without insurance coverage for GLP-1 drugs face unique challenges in staying on these treatments, so their inclusion in research on adherence is essential.

WeightControl.com Interview with:
Patricia Rodriguez PhD MPH
Principal Applied Scientist
Truveta Research

Ty J. Gluckman, MD, MHA
Center for Cardiovascular Analytics
Research and Data Science (CARDS)
Providence Heart Institute
Providence Health System
Portland, Oregon

Ezekiel J. Emanuel, MD, PhD
Healthcare Transformation Institute
Department of Medical Ethics and Health Policy
Perelman School of Medicine
University of Pennsylvania, Philadelphia

WeightControl.com: What is the background for this study?

Response: “Millions of Americans could benefit from GLP-1s, but clinical trials suggest that patients need to stay on these drugs to experience sustained benefits. We were interested in using data from patients across the country to understand whether patients are staying on these drugs, and what barriers may exist to continued use.

We looked at about 125,000 patients who started GLP-1 medications and found that a majority of patients stop taking them within one year. About 65% without type 2 diabetes (T2D) stopped within one year, compared with 47% of those with T2D.

Pages: 12

GLP-1 Receptor Agonists Found Effective for Weight Loss Among Adults Without Diabetes

Since there is a lack of head-to-head trials on these agents, future research should explore their comparative efficacy (e.g. semaglutide vs. tirzepatide vs. retatrutide).

WeightControl.com Interview with:

Areesha Moiz BSc
Centre of Clinical Epidemiology, Lady Davis Institute
Jewish General Hospital, and Division of Experimental Medicine
McGill University, Montreal, Quebec, Canada
Division of Experimental Medicine
McGill University

WeightControl.com: What is the background for this study?

Response: GLP-1 receptor agonists have been used for type 2 diabetes management for almost two decades. Trials conducted in this patient population also showed some weight loss effects, leading to them being investigated in patients with overweight or obesity and without diabetes. With all the recent buzz around Ozempic (semaglutide) these past few years, we were interested in seeing what other agents in this class of drugs were out there, how they performed for weight loss, and how safe they were.

Pages: 12

Healthy Diet May Help With Pain Management, Regardless of Person’s Size

Fhe study found that diet quality could affect pain differently in men and women. Women who consumed a higher quality diet reported lower pain and had better physical function. This effect was less pronounced in men.

WeightControl.com Interview with:
Dr. Alison M Hill | PhD, APD, RNutr, MDiet, BAppSci (Human Movement) Hons.
Senior Lecturer in Nutrition
UniSA: Clinical and Health Sciences
Alliance for Research in Exercise, Nutrition and Activity (ARENA)
University of South Australia

WeightControl.com: What is the background for this study?

Response: Chronic pain is a common and disabling health problem, estimated to affect 20-30% of people worldwide. Those who experience chronic pain often have a higher weight compared to the general population. Food choices that influence the overall quality of a person’s diet may contribute to an individual’s pain by affecting their weight or triggering bodily processes such as inflammation.

This study of Australian adults explored whether diet was directly linked to pain, and if factors like weight, or body fat, impacted this relationship. Additionally, the study looked at differences between men and women as chronic pain is more prevalent in women.

Pages: 12

Henry Ford Study Finds Less Alcohol Intake in Patients on Obesity Medications

Lisa Miller-Matero, PhD
Associate Scientist & Associate Director of Health Services Research
Henry Ford Health

What was exciting was that those who were drinking at higher or even what is considered hazardous levels had a greater likelihood of reducing alcohol use.

WeightControl.com: What is the background for this study?

Response: We partnered with colleagues at Weight Watchers (WW International) on this project after they began receiving reports from their members that they noticed reduced desire for alcohol use. Though there has been some research conducted in animal studies, research in humans has been lacking, especially examining changes in alcohol use.

Ohio State University Studies Changes in Food Waste Among New Weight Loss Drug Users

When an increasingly large segment of consumers is buying less food and perhaps wasting less food, it can reverberate through the food system

WeightControl.com Interview with:
Brian E. Roe, Ph.D.
Associate Chair
Fred N. VanBuren Professor of Farm Management
The Ohio State University

WeightControl.com: What is the background for this study?

Response: The use of anti-obesity medications (AOMs) is on the rise in the United States with the introduction of glucagon-like peptide-1 (GLP-1) receptor agonists to the pharmaceutical market. It is estimated that 6% of the U.S. adult population is on a GLP-1 medication while as many as 12% have been on one at some point. While it is well-documented that people eat less food when on the drug, little is known about its impact on how much food consumers waste, which is critical because about a third of food purchased is never consumed.

ObesityWeek: GLP-1 Therapy Increases Fat Metabolism as Well As Making You Eat Less

Treatment of obesity is more complicated than simply eat less and move more – and these newer GLP-1 based therapies are increasing fat tissue metabolism as well as making you eat less.

WeightControl.com Interview with:
Prof Donal O’ Shea MB, BCh, BAO, MD, FRCPI, FRCP (UK)
UCD School of Medicine
UCD Health Sciences Centre
University College Dublin

WeightControl.com: What is the background for this study?

Response: Glucagon‐like peptide‐1 (GLP‐1) analogs are powerful weight‐loss treatments. These analogs are believed to act primarily by having a major impact on energy intake through delaying gastric emptying and promoting satiety.

We felt this was over simplistic and that it was likely that GLP-1 treatments also had an effect on the other side of the energy balance equation through increasing metabolic activity in fat tissue.

Pages: 12

Obesity Drugs: More Protein Needed to Offset Muscle Loss

Multiple studies now report that the amounts of skeletal muscle loss with these new powerful weight loss agents is quite large, up to 40% of weight loss.

WeightControl.com Interview with:

Steven B. Heymsfield, M.D.
Professor and Director of the Body Composition-Metabolism Laboratory
Pennington Biomedical Research Center of the
Louisiana State University System in Baton Rouge

WeightControl.com: What is the background for this study?

Response: The recent introduction of glucagon receptor-1 agonists for weight control opens a new era in obesity pharmacotherapy. The greater weight loss with the new drugs is revealing a long-standing recognition that negative energy balance is accompanied by not only decrements in body fat, but also lean protein-containing tissues such as liver, kidney, and skeletal muscle.

Sex Differences in Fat Metabolism after Fasting

WeightControl.com Interview with:
Stéphanie Abo, PhD
Applied Mathematics
University of Waterloo

WeightControl.com: What is the background for this study?

Response: Our study examines how men and women process food differently, particularly how each sex responds to a high-carb versus a high-fat diet. Obesity and related conditions, like type 2 diabetes, are major global issues, and nutrition plays a key role in managing these conditions.

Men and women metabolize fats and carbohydrates differently, especially during fasting and exercise. Using a mathematical model and computer simulations, we investigated sex differences in the processing of glucose and fat and identified candidate pathways behind these sex-specific differences. This research can help improve personalized nutrition and diet strategies for both men and women.